-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
According to the China Drug Clinical Trial Registration and Information Disclosure Platform, Nanjing Zhengxiang Pharmaceutical Co.
Screenshot source: Drug clinical trial registration and information disclosure platform
Founded in 2018, Zhengxiang Medicine is a clinical-stage biomedical company focusing on the research and development of small molecule new drugs for cancer, viral infections and autoimmune diseases
According to information on Zhengxiang's official website, ZX-7101A is a new generation of oral anti-influenza drug independently developed by the company
According to a press release issued earlier Zheng Xiang pharmaceutical, pharmacokinetic and pharmacological properties of ZX-7101A can meet single administration for the prevention and treatment of influenza A and influenza B
This is a randomized, double-blind, placebo-controlled, single-dose escalation and food-effect phase 1 clinical study.
Influenza is a respiratory infectious disease caused by influenza virus, which is a serious harm to human health
references:
[1] China Drug Clinical Trial Registration and Information Disclosure Platform.
[3] Technical Guidelines for Influenza Vaccination in China (2021-2022).
